Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

Hyperlipidemias Clinical Trial

Official title:

A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02719028
• Other study ID #: GHLIP-2-001
• Status: Completed
• Phase: Phase 2
• Start date: May 2016
• Est. completion date: March 31, 2019

Study information

• Verified date: December 2019
• Source: Golden Biotechnology Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.

Description:

The primary efficacy objective is to demonstrate the reduction of triglyceride (TG) by Antroquinonol, in comparison with placebo, after 12 weeks of treatment in patients with hypercholesterolemia and hyperlipidemia. Secondary objectives include the evaluation of the effects of Antroquinonol in comparison with placebo on other lipid parameters after 12 weeks of treatment and the effects of Antroquinonol on left ventricular diastolic function, arterial stiffness and fatty liver. The safety and tolerability of Antroquinonol will be monitored as well.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: March 31, 2019
• Est. primary completion date: September 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adults of either sex 30 to 75 years of age, inclusive, with a diagnosis of nonfamilial hypercholesterolemia or mixed hyperlipidemia as one of the following:

• TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL

• TG between 150 mg/dL and 500 mg/dL and LDL-C > 130 mg/dL);

2. Subject must be free of any clinically significant disease, other than nonfamilial hypercholesterolemia or mixed hyperlipidemia that would knowingly interfere with study evaluations;

3. A wash-out period of 2 weeks will be applied to patients prior treated with lipid-lowering medication;

4. Subject must be willing to adhere to protocol requirements, and provide written informed consent;

5. Female of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria:

1. Patients with secondary dyslipidemia caused by diabetes mellitus, hypothyroidism, obstructive liver disease, chronic renal failure or drugs which can increase LDL-C level (e.g. retinoids, cyclosporine A and phenothiazines) or decrease HDL-C level (e.g. progestins, androgens, ß-blockers, probucol and anabolic steroid)

2. Patients with lifestyle that may interfere treatment efficacy, such as alcoholism or drinking habits more than 3 times per week, late dinner, late night supper, frequent oversea business traveler, frequent social gathering, and patients who cannot anticipate a diet control and lifestyle changes;

3. Patients with diabetes or history of coronary artery disease (has had myocardial infarction, cardiac intervention, cerebrovascular accident/stroke or transient ischemic attack less than 6 months prior to Visit 1);

4. Patients with hypertension that is uncontrolled defined as 2 consecutive measurements of sitting blood pressure of systolic >140 mmHg or diastolic > 90 mmHg at Visit 1;

5. Patient has a known hypersensitivity to Antroquinonol or related compounds;

6. Patient with uncontrolled intercurrent illness including, but not limited to, acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require IV therapy), right heart failure due to severe pulmonary disease, diagnosed peripartum or chemotherapy induced cardiomyopathy within the 12 months prior to visit 1, or psychiatric illness/social situations that would limit compliance with study requirements;

7. Patients with a history of heart transplant or who are on a transplant list or with left ventricular assistance device (LVAD device);

8. Patients with documented ventricular arrhythmia with syncopal episodes within the past 3 months prior to visit 1 that remained untreated;

9. Patients with confirmed severe primary pulmonary, renal (eGFR<30 ml/min/1.73 m2) or hepatic (Child-Pugh B/C classification) disease;

10. Patients who can't stop current lipid lowering drug treatments based on investigator's judgement;

11. Patients with any malignancy, treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin or carcinoma in situ of the cervix;

12. Female patient during pregnancy, lactation or breastfeeding;

13. Patient has any other life-threatening complications;

14. Patient who is considered unreliable as to medication compliance or adherence to scheduled appointments, or inappropriate for inclusion determined by the investigators;

15. Any other reasons addressed by the investigators.

Related Conditions & MeSH terms

• Hypercholesterolemia
• Hyperlipidemias
• Hyperlipoproteinemias

Intervention

Drug:
• Antroquinonol
Antroquinonol will be provided as capsules of 50 mg
• placebo
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Locations

Country	Name	City	State
Taiwan	Chang Gung Memorial Hospital, Linkou branch	New Taipei City
Taiwan	Far Eastern Memorial Hospital	New Taipei city
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Golden Biotechnology Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TG Change (mg/dL )	value at 12 weeks minus value at baseline	12 weeks
Secondary	LDL& HDL (mg/dL)	value at 12 weeks minus value at baseline of PP pupulation in HDL/LDL ratio.	12 weeks
Secondary	Non-invasive Arterial Stiffness Measurement	To evaluate the effect of Antroquinonol via a non-invasive arterial stiffness measurement.	12 weeks
Secondary	Fatty Liver	To evaluate the recover fatty liver effect of Antroquinonol on patients who with fatty liver by Investigator	12 weeks